pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
siRNA · news · pharmadog
← back to siRNA
News · siRNA
29
stories
6d
Capricor soars on potential FDA review extension, filing amendments
biospace
7d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
9d
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
biospace
9d
Epicrispr raises $90M to rewrite treatment of rare muscle disease
fiercebiotech
10d
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
10d
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
endpoints
11d
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
15d
STAT+: Why Schrödinger CEO Ramy Farid changed how he’s thinking about AI
stat
15d
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
20d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
23d
Webinar: Building the Intelligence Engine for Drug Discovery R&D Teams
biospace
23d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
24d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
27d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
29d
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
biopharma dive
29d
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
biospace
Jun 8, 26
City banks nearly $100M for next-gen RNAi drugs
biopharma dive
Jun 8, 26
City Therapeutics gets $99M to gather data on three RNAi medicines
endpoints
Jun 4, 26
STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
stat
Jun 4, 26
STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
stat
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 4, 26
STAT+: AI titans push Congress for DNA safeguards
stat
Jun 4, 26
Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
stat
Jun 3, 26
STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
stat
May 7, 26
Sarepta tumbles as its gene therapy sales decline further
biopharma dive
May 6, 26
GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
endpoints
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77M
fiercebiotech
